Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Heyndrickxia coagulans + Inulin-type fructans (ITF) / Inulin & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

IRCT20100524004010N23 - Heyndrickxia coagulans GBI-30 - 6086 + Inulin-type fructans (ITF) / Inulin & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

This randomized, double-blind, placebo-controlled clinical trial revealed that a 12-week supplementation regimen with
Heyndrickxia coagulans GBI-30 - 6086 + Inulin-type fructans (ITF) / Inulin is advantageous for treating [Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)](brain://0_T4lKylP0CsXkdsY4SiLw/NonAlcoholicFattyLiverDiseaseNafldMetabolicDysfu…

References (Sources)

The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial
Abhari et al. 2020 Clin Nutr ESPEN 39: 53-60

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!